Cerity Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cerity Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,446	Closed	-$2.7M	–	2787
2025 Q1	$2.7M	Sell	20,446 -20,997	-51%	-$2.62M	0.01%	985
2024 Q4	$3.16M	Sell	41,443 -2,664	-6%	-$219K	0.01%	907
2024 Q3	$3.23M	Buy	44,107 +17,027	+63%	+$1.28M	0.01%	878
2024 Q2	$1.85M	Sell	27,080 -7,047	-21%	-$489K	﹤0.01%	942
2024 Q1	$2.36M	Buy	34,127 +30,417	+820%	+$2.09M	0.01%	898
2023 Q4	$266K	Buy	+3,710	New	+$213K	﹤0.01%	1580

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cerity Partners's ITCI Position: Q2 2025 in Review

Cerity Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 20,446 shares — an estimated $2.7M sold.

Cerity Partners first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $3.23M in Q3 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Cerity Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Cerity Partners sold 20,446 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.7M.
Cerity Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
Cerity Partners's Intra-Cellular Therapies Inc. position peaked at $3.23M in Q3 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Cerity Partners's 13F filing for Q2 2025, filed 13 Aug 2025.